Table of Contents Author Guidelines Submit a Manuscript

Cancer Diagnostic and Predictive Biomarkers

Call for Papers

The Omics revolution along with the Next Generation Sequencing has recently opened the possibility to identify molecular changes and metabolic pathways specific for each cancer with the resulting possibility of further molecular subclassification of each cancer histotype and identification of a more reliable prognosis and appropriate treatment. A further result is the reduction of overtreatment of those with higher responsivity and better prognosis. Furthermore, such studies do have the possibility of identifying specific cancer targets, with higher effectiveness of chemotherapy and much lower general toxicity. The whole field is in a current turmoil, and a specific issue focused on the clinical validation of newly identified biomarkers, able to bridge molecular mechanisms with clinical diagnosis and therapeutic responsivity, should be very successful and attract the entire scientific community. Potential topics include, but are not limited to:

  • Biomarkers in pathogen-related cancers
  • Biomarkers of cancer progression
  • Inflammation-related biomarkers in cancer diagnosis and progression
  • miRNA as a biomarker of cancer progression and therapeutic targets
  • Epigenetic biomarkers in cancer immunology
  • Tissue cancer biomarkers for targeted therapy
  • Plasma/serum markers for clinical diagnosis and followup

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Manuscript DueFriday, 30 August 2013
First Round of ReviewsFriday, 22 November 2013
Publication DateFriday, 17 January 2014

Lead Guest Editor

  • Franco M. Buonaguro, Department of Experimental Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

Guest Editors

  • David Pauza, Department of Microbiology and Immunology, Institute of Human Virology, Baltimore, MD, USA
  • Maria Lina Tornesello, Department of Experimental Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
  • Pierre Hainaut, Department of Research, International Prevention Research Institute, Lyon, France
  • Renato Franco, Department of Pathology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
  • Francesco M. Marincola, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD, USA